Research and Markets: Risk Evaluation and Mitigation Strategies (REMS) Trends and Implications for BioPharma

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/f36bab/risk_evaluation_an) has announced the addition of the "Risk Evaluation and Mitigation Strategies (REMS) Trends and Implications for BioPharma" report to their offering.

On September 27, 2007, the Food and Drug Administration Act of 2007 (FDAAA) was signed into law. FDAAA 2007 included several key provisions, and gave FDA the authority to require a Risk Evaluation Mitigation Strategy (REMS) from drug sponsors. The primary objective of REMS is to enhance drug safety by ensuring that the benefits of a drug outweigh its risks. FDAAA 2007 became effective on March 25, 2008, when the FDA approved 16 drugs with existing RiskMAPs as meeting the requirements for REMS. REMS differ from previous risk management approaches (e.g., Risk MAPs) in several significant regards; they are well defined, assessed over time and legally enforceable.

REMS can range from a simple Medication Guide and Assessments of REMS implementation and effectiveness to programs that include Communication Plans with healthcare providers and complex distribution restrictions Elements to Assure Safe Use (ETASU). Of the various components of REMS, ETASU represents the greatest challenge. ETASU can include restrictions on various stakeholders (e.g., provider, physician, patient), and are ultimately distribution restrictions. Entereg was the first new product for which the FDA required this restrictive element (May 2008), although a number of drugs with RiskMAPs approved prior to 2008 were deemed to have met the requirements for REMS including ETASU (e.g., Accutane, Tysabri). Since then, the agency has required ETASU for >20 products: 4 in 2008, 5 in 2009 and 12 in 2010.

This report reviews 157 REMS for NDAs and BLAs implemented from March 2008 until the end of 2010. We analyze the yearly percentage of new molecular entity (NME), new drug application (NDA) and biologics license application (BLA) requiring REMS from 2008-2010. The data is also segmented by NDA chemical type (e.g., new formulation, new combination, new indication) and review classification (e.g., priority review, standard review, orphan drug).

We review historical trends, and forecast six future key trends in REMS requirements based on data in the last 3 years and interviews with industry experts. Trends discussed address issues such as REMS pervasiveness, change in REMS requirements, REMS streamlining, stakeholder input and more.

Given that REMS are likely to impact a significant number of drugs, we review the key implications for BioPharma, including drug approval rates and timelines, cost of commercialization and drug utilization/uptake. We discuss three distinct ways in which REMS can decrease a drugs addressable patient population, as well as the impact of REMS on cash flow and drug valuation. Finally, we examine how REMS programs can be leveraged as opportunities for drug commercialization; we outline strategic, operational and organizational best practices adopted by sponsors to deal with REMS.

Key Topics Covered:

Abstract

Executive summary

Introduction

  • Context
  • History of risk management
  • Description of REMS
  • FDA review
  • Criteria for REMS

Key trends

  • Historical REMS trends
  • Future REMS trends

Implications for BioPharma

  • Impact of REMS
  • Likelihood of receiving REMS
  • Strategic consequences for BioPharma sponsors

Appendix

  • Opioid class REMS
  • REMS by NDA review classification
  • REMS elements by application
  • Complexity of REMS over time
  • Abbreviations
  • List of REMS analyzed in this report
  • List of exhibits

For more information visit http://www.researchandmarkets.com/research/f36bab/risk_evaluation_an



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.